Researchers at the University of Texas MD Anderson Cancer Center paired NK cells with a second chimeric antigen receptor (CAR) to act as a logic gate and thus requires two signals to eliminate a target cell (Nature Medicine, September 29, 2022). They studied clinical samples from patients with lymphoid malignancies treated with anti-CD19 CAR NK cells.

In the study, researchers confirmed higher levels of the CD19 antigen on CAR NK cells were associated with lower levels of CD19 on tumor cells and a higher probability of relapse. To stop this from happening, the scientists added an inhibitory CAR designed to recognize a marker unique to NK cells. That resulted in CAR NK cells not killing their sibling cells, even if the cells had the tumor antigen on their surface.

In preclinical models, the logic-gated CAR NK cells were better able to focus on and attack only the tumor cells, which reduced the frequency of NK cell exhaustion and fratricide as well as improved antitumor activity.

Why does this happen? The engineered cells can ignore the tumor antigen due to the physiological process trogocytosis, according to the researchers, who contend their work provides a further understanding of CAR NK biology and suggests that clinical evaluation of the dual-CAR strategy is warranted.

"It's important to prevent tumor escape following CAR NK therapy because that has led to relapse in some patients. By preventing exhaustion and fratricide in CAR NK cells, we can further improve their activity and function," corresponding author Dr. Katy Rezvani, PhD, professor of stem cell transplantation and cellular therapy, said in a statement. "We are excited to translate this research to the clinic, as this is something that could be applied to any CAR NK cell therapy."

Blocking key enzyme boosts anticancer T-cell responses, resistance to immunosuppression
Blocking a key enzyme boosts anticancer T-cell responses and resistance to immunosuppression, according to a mice study from LSU Health New Orleans published...

Plant virus, antibody activates immune system's 'natural killer' cells
University of California, San Diego researchers have shown in a study that a new combination therapy to combat cancer may one day consist of a plant virus...

Experimental drug enhances immunotherapy against pancreatic cancer in mice
A combination treatment that included an experimental small molecule drug not only led to a reduction in tumor growth in murine models of pancreatic cancer,...

Heat-controlled CAR T cells show improved cancer-killing ability
By adding a genetic on-off switch to engineered CAR T cells, researchers have developed a remote-controlled system that enables precision invasion of...

CAR-NK cells hold promise for solid tumors
A new cancer immunotherapy that leverages the ability of natural killer (NK) cells to discriminate between cancer and normal cells has shown promise in...